ADMA Biologics Faces Securities Fraud Class Action Lawsuit

The complaint filed against ADMA Biologics claims the company artificially inflated its financial standing through undisclosed related-party transactions and the practice of channel stuffing. Plaintiffs argue these actions created a deceptive appearance of revenue, masking significant weaknesses in the firm's internal controls. According to the filing, these false and misleading statements collapsed when the market uncovered the company's true financial condition, resulting in direct losses for shareholders.

Schall, Brown & Schwartz LLP is currently seeking lead plaintiffs for the action. While the class has not yet been certified, affected investors may contact attorneys Brian Schall or David Schwartz to discuss potential recovery efforts. Participation in the lawsuit does not require an immediate appointment as a lead plaintiff, and those who choose not to join remain absent class members until the court formalizes the case.